The new immuno-oncology company is betting a next-generation CTLA-4 antibody with a short half-life can crack “cold” colon tumors that resist today’s immunotherapy.
An intravenous gene therapy extended survival up to threefold and eased symptoms in cats with Sandhoff disease — an early but hopeful step toward treating a disorder that usually kills children by age four.
Studies increasingly tie Helicobacter pylori infection to colorectal cancer, but whether treating the bug lowers that risk remains genuinely unsettled.
At a major lung conference, AstraZeneca reported that its IL-33 inhibitor tozorakimab significantly reduced the airway-clogging mucus plugs that worsen COPD.
ARPA-H’s new ADVOCATE program aims to build the first FDA-authorized “agentic” AI that can autonomously adjust heart-failure care — assessing symptoms, ordering labs, even prescribing.
A 15,000-person Swedish study found people with bipolar disorder taking semaglutide had a 21% lower risk of psychiatric hospitalization — an intriguing signal, but not proof, and not seen with every GLP-1 drug.
Del-desiran, the lead muscle-disease therapy Novartis bought with Avidity for $12 billion, missed its main goal in myotonic dystrophy — sending the stock to its worst day since 2020.
A new American Cancer Society–WHO analysis projects annual cancer diagnoses rising from 21 million to 34 million by 2050, driven mostly by aging and population growth — with the heaviest burden falling on poorer countries.
A 132,000-person Danish study found people who began statins within a year of a type 2 diabetes diagnosis had a 15% lower 10-year dementia risk — though it can’t prove the drugs are the cause.
BrainChild Bio is betting that delivering engineered immune cells directly into the brain — not through the bloodstream — can finally reach some of the deadliest childhood cancers.
After the drug lowered inflammation but not heart attacks in a big Phase 3, a monitoring committee judged two follow-on trials unlikely to succeed — a setback for the “inflammation causes heart disease” strategy.
The deal brings GSK a first-in-class “antibody-targeted therapy conjugate” that hits EGFR and KRAS at once — a design meant to aim a potent KRAS blocker straight at tumors.